Krishna Institute of Medical Sciences
Mainboard₹2,144 Cr issue
+22.29%
Listing gain over issue price
Issue size
₹2,144 Cr
1 lot at cut-off
₹14,850
Lot size
18shares
Open
16 Jun 2021
Close
18 Jun 2021
Allotment
23 Jun 2021
Listing
28 Jun 2021
Listing performance
Issue price
₹825
Listed at
₹1,008.90
Listing-day close
₹996.95
Latest price
₹665.15
Close on 23 Oct 2026
Listing gain
+22.29%
Return since issue
+303.12%
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Issue details
- IPO date
- 16 Jun 2021 – 18 Jun 2021
- Listing date
- 28 Jun 2021
- Face value
- ₹10 per share
- Issue price
- ₹825 per share
- Lot size
- 18 shares
- Total issue size
- ₹2,144 Cr
- Market cap at offer price
- ₹6,602 Cr
- Promoter holding
- 46.81% → 38.84% pre-issue → post-issue
- ISIN
- INE967H01025
- Registrar
- MUFG Intime India Pvt.Ltd.
- Lead managers
- Axis Capital Ltd.
- Registered office
- D.No.1-8-31/1, Minister’s Road, Secunderabad 3, Telangana
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Anchor investor · within QIB | 1,15,84,060 | — | — |
| Market maker | 0 | — | — |
Application size
Minimum 18 shares per lot, in multiples, at ₹825
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 18 | ₹14,850 |
| Retail (max) | 13 | 234 | ₹1,93,050 |
| S-HNI (min) | 14 | 252 | ₹2,07,900 |
| S-HNI (max) | 67 | 1,206 | ₹9,94,950 |
| B-HNI (min) | 68 | 1,224 | ₹10,09,800 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Shares allocated
1,15,84,060
Anchor portion
₹956 Cr
at ₹825 per share
Valuation and performance
Valuation at offer price
₹825 per share
| Metric | Pre-issue | Post-issue |
|---|---|---|
| Market cap | — | ₹6,602 Cr |
About Krishna Institute of Medical Sciences
Krishna Institute of Medical Sciences Limited was incorporated on July 26, 1973, and converted to a public limited company on January 29, 2004. The company operates a network of multi-specialty hospitals under the "KIMS Hospitals" brand across Andhra Pradesh and Telangana states. As of March 31, 2021, it operated nine multi-specialty hospitals with an aggregate bed capacity of 3,064 beds including over 2,500 operational beds. The company provides multi-disciplinary integrated healthcare services in Tier 1, 2, and 3 cities, offering services across over 25 specialties and super specialties including cardiac sciences, oncology, neurosciences, gastric sciences, orthopaedics, organ transplantation, renal sciences, and mother and child care. The company earns revenue from in-patient and out-patient healthcare services provided at its hospitals and related facilities.
Company Analysis
from RHPKrishna Institute of Medical Sciences Limited is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana, operating nine multi-specialty hospitals with over 3,000 beds and offering services across 25+ specialties including cardiac sciences, oncology, and organ transplantation.
Krishna Institute of Medical Sciences Limited was incorporated on July 26, 1973, and converted to a public limited company on January 29, 2004. The company operates a network of multi-specialty hospitals under the "KIMS Hospitals" brand across Andhra Pradesh and Telangana states. As of March 31, 2021, it operated nine multi-specialty hospitals with an aggregate bed capacity of 3,064 beds including over 2,500 operational beds. The company provides multi-disciplinary integrated healthcare services in Tier 1, 2, and 3 cities, offering services across over 25 specialties and super specialties including cardiac sciences, oncology, neurosciences, gastric sciences, orthopaedics, organ transplantation, renal sciences, and mother and child care. The company earns revenue from in-patient and out-patient healthcare services provided at its hospitals and related facilities.
Healthcare servicesHospital operationsMedical careSpecialty healthcare
Objects of the Issue
- Repayment/pre-payment, in full or part, of certain borrowings availed by our Company and our Subsidiaries viz. KHKPL, SIMSPL and KHEPL ₹1,500.00 million p.19
- General corporate purposes ₹416.60 million p.19
- Repayment of borrowings of subsidiaries KHKPL and SIMSPL ₹1,094.00 million p.100
- Funding capex for expansion of existing hospital facilities and setting up new facilities ₹701.76 million p.100
- General corporate purposes ₹416.60 million p.54
- Repayment/pre-payment, in full or part, of certain borrowings availed by our Company and by our Subsidiaries viz KHKPL, SIMSPL and KHEPL ₹1,500.00 million p.103
- General corporate purposes ₹416.60 million p.103
- Fresh Issue by the Company for general corporate purposes and working capital ₹2,000.00 million p.382
Issue Structure
- Total Issue
- ₹21,437.44 million
- Fresh Issue
- ₹2,000.00 million (2,436,595 equity shares including 254,777 shares at ₹785 for Employee Reservation)
- Offer for Sale
- ₹19,437.44 million (23,560,538 equity shares)
- Price Band
- ₹815 to ₹825 per equity share (Floor Price ₹815, Cap Price ₹825)
- Lot Size
- 18 Equity Shares and in multiples of 18 Equity Shares thereafter
- Face Value
- ₹10 per equity share
Business Model
The company generates revenue through the provision of multi-disciplinary integrated healthcare services including in-patient hospital services, out-patient consultations, diagnostic services, organ transplantation, fertility services, and related pharmaceutical and medical services. Revenue is earned from patient fees, government health schemes (including CGHS, Aarogyasri Scheme, and AP Employee Health Scheme), and insurance programs.
Business Segments
In-patient and out-patient healthcare services provided through nine multi-specialty hospitals operating under the KIMS Hospitals brand
Operates multi-specialty hospitals providing inpatient and outpatient services, diagnostic services, blood banks, and pharmacy operations
Multi-specialty tertiary care hospital offering cardiac sciences, renal sciences, gastric sciences, orthopaedics, neuro sciences, and other specialties
Multispecialty hospital with 200 beds (150 operational as of March 31, 2021); serves mother & child care, cardiac sciences, renal sciences, gastric sciences, neuro sciences, orthopaedics and oncology
Multi-specialty hospital with 200 operational beds; focuses on mother & child, cardiac sciences, renal sciences, gastric sciences, orthopaedics, neuro sciences
Multi-specialty hospital with 250 beds (215 operational as of March 31, 2021); serves cardiac sciences, orthopaedics, renal sciences, neuro sciences, mother & child and gastric sciences
Comprehensive range of cardiac services treating cardiovascular disorders from preventive programs to complicated surgeries including heart transplants, coronary bypass operations, heart valve repairs, angioplasties, cardiac catheterizations, and cardiac assist device implantation.
Comprehensive care for neurological disorders including brain, spinal cord and peripheral nerve disorders. Services include treatment of Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, epilepsy and brain tumors with neuro-imaging and monitoring technology.
Multidisciplinary care for organ transplantation including heart, lung, liver, pancreas and kidney transplants with patient-focused outpatient services and treatment of complex liver and pancreatobiliary diseases.
Range of oncology treatments including medical oncology, surgical oncology and radiation oncology. Services include modern multidisciplinary treatment of primary and metastatic tumors with specialization in prostate, ovarian and brain cancers.
Complete range of consultative, diagnostic and treatment services for kidney diseases from earliest detectable changes through end stage kidney diseases, including haemodialysis and peritoneal dialysis.
Comprehensive care in orthopaedics including sports injuries, spine procedures, trauma, joint/knee/hip replacements, and pediatric orthopaedics with surgical expertise in tissue repair and total joint reconstruction.
Services for prevention, diagnosis, and treatment of gastrointestinal system diseases offering care in both medical and surgical gastroenterology for diseases of oesophagus, stomach, intestines, pancreas, gallbladder, and liver.
Wide range of medical and surgical specialties for women and children including obstetrics, gynaecology, paediatrics, neonatology, foetal medicine, and reproductive science services (IUI, IVF, ICSI).
Establishing, constructing, erecting, maintaining, running, managing, developing, owning, acquiring, purchasing hospital facilities, dispensaries, clinics, diagnostic centers, polyclinics, pathology laboratories, nursing homes, physiotherapy centers and other similar medical establishments for providing treatment and medical relief
Provides inpatient and outpatient hospital services including accommodation, surgery, medical/clinical professional services, food and beverages, investigation and supply of pharmaceutical and related products
Sale of pharmacy items to customers
Provides medical education through academic courses with associated tuition fees
Inpatient hospital services including accommodation, surgery, medical/clinical professional services, food and beverages, investigation and supply of pharmaceutical and related products for admitted patients.
Outpatient hospital services including medical consultations, diagnostics, investigations and treatments provided on an out-patient basis.
Provision of healthcare services including inpatient and outpatient treatment, medical procedures, and use of medical devices and surgical instruments
Sale of medicines, consumables and related pharmaceutical products
Academic courses, sale of food and beverages, and other hospital income
SWOT Analysis
Strengths
- • One of the largest corporate healthcare groups in AP and Telangana(p.20)
- • Significant bed capacity across multi-specialty hospitals(p.20)
- • Broad service portfolio across 25+ specialties(p.20)
- • Strong financial performance with growing profitability(p.21)
- • Improving earnings per share trajectory(p.21)
- • Regional leadership in clinical excellence and affordable healthcare delivery(p.111)
- • Strong track record of operational and financial performance(p.111)
- • Ability to attract and retain high-quality medical talent(p.111)
- • Disciplined approach to inorganic growth through successful acquisitions(p.111)
- • Experienced senior management with strong institutional shareholder backing(p.111)
- • Well-positioned consolidator in large unorganized healthcare market(p.111)
- • Market leadership in AP and Telangana with 2.2x more beds than second largest provider(p.170)
- • Superior financial performance with highest revenue and EBITDA in region(p.170)
- • Affordable pricing model with 41% lower ARPP than industry average(p.171)
- • Exceptional doctor retention rate of over 80% since inception(p.171)
- • Strong operational efficiency with ROCE of 26.90% across markets(p.171)
- • Highest cardiac treatment market share in AP with 18.20%(p.170)
- • 20+ years of regional expertise with strong brand recognition(p.170)
- • Leading medical education capacity with 230 DNB and post-doctoral fellows(p.169)
- • Established network of multiple hospital subsidiaries across India(p.250)
- • Diversified revenue streams from hospital services and pharmacy operations(p.283)
- • Strong liquidity position with substantial cash and bank balances(p.276)
- • Significant ownership by General Atlantic Singapore, a leading global investor(p.277)
- • Profitability improvement with positive retained earnings trend(p.278)
- • Largest corporate healthcare group by patient volume and treatments in AP/Telangana(p.322)
- • Multi-specialty integrated healthcare with comprehensive service coverage across 25+ specialties(p.322)
- • Significant hospital network: 9 hospitals with 3,064 beds across strategic geographies(p.322)
- • Strong operational metrics with high occupancy and efficient ALOS management(p.322)
- • Capital efficient expansion model with disciplined capex per bed below industry average(p.322)
- • No customer concentration risk with diversified patient base(p.299)
- • Revenue growth trajectory with 20.59% CAGR in hospital revenue (2019-2021)(p.324)
- • Strong profitability with 23.30% return on net worth for FY2021(p.314)
Weaknesses
- • High attrition among healthcare professionals(p.31)
- • Heavy revenue concentration in Hyderabad hospitals(p.33)
- • Dependence on few specialties for majority of revenue(p.33)
- • KIMS Kondapur lacks occupancy certificate and fire NoC(p.34)
- • Significant debt with restrictive covenants(p.36)
- • Majority of doctors are not employees and work on consultancy basis(p.31)
- • Incomplete documentation for one Promoter(p.34)
- • Promoters faced capital market restrictions and demat account freeze due to association with APL(p.40)
- • Executive Director currently listed as disqualified director by MCA due to past directorship failures(p.40)
- • Significant trade receivables and credit impairment risk from payers(p.40)
- • Dependence on third-party payers with termination risk and ongoing disputes(p.40)
- • Trademark applications facing opposition from entities holding similar marks(p.40)
- • Limited geographic presence with high concentration in two states(p.41)
- • Net loss in FY2019 and history of incurring losses(p.45)
- • High dependence on key personnel including promoters for strategic direction(p.46)
- • Significant historical non-compliance and missing corporate records prior to 2003(p.55)
- • Non-compliance with Companies Act in 2005 preferential allotment to more than 49 persons(p.43)
- • Fire noC rejection for one hospital building affecting operations(p.49)
- • One hospital building lacks required occupancy certificate and fire NoC(p.30)
- • History of preferential allotment non-compliance with potential future regulatory action(p.43)
- • Limited historical corporate records and documentation prior to 2003(p.88)
- • Past regulatory filing discrepancies and omissions with RoC(p.91)
- • Subsidiaries (KHKPL, SIMSPL) currently operating at losses(p.105)
- • Material debt obligations requiring repayment from IPO proceeds(p.104)
- • High promoter shareholding concentration creating governance considerations(p.94)
- • Geographic concentration entirely in AP and Telangana(p.170)
- • Negative outpatient volume CAGR of -3.96% from 2019 to 2021 due to COVID-19(p.169)
- • High concentration of revenue from top 10 doctors at 21.80% of total income(p.169)
- • Dependence on out-of-pocket payments at 62.90% of total income(p.186)
- • Only one hospital on traditional lease, creating operational complexity(p.171)
- • Trademark registration blocked by opposition applications across all classes(p.191)
- • Limited historical records prior to 2003 takeover(p.201)
- • Dependence on few customers through government schemes(p.200)
- • Significant debt burden with total borrowings of Rs. 2,704.68 million(p.297)
- • High concentration of trade receivables credit risk with significant credit-impaired amounts(p.276)
- • Contingent liabilities relating to multiple tax disputes and medical claims(p.285)
- • Dependence on key related party transactions and promoter guarantees(p.280)
- • Accumulated losses and negative retained earnings historically(p.278)
- • High consultancy charges representing significant expense (19.66% of total income in FY2021)(p.325)
- • Material medical consumables and drug costs (21.56% of total income in FY2021)(p.325)
- • Significant employee benefits costs at 16.43% of total income in FY2021(p.325)
- • Elevated total debt at ₹2,704.68 million with debt-to-equity ratio of 0.31(p.321)
- • Negative outpatient volume CAGR of (3.96)% from 2019-2021 due to COVID-19 impact(p.323)
- • Unresolved tax disputes relating to luxury tax and service tax liabilities(p.311)
- • High reliance on consultancy fees creating significant operating costs(p.347)
- • Dependence on multi-specialty hospital model with concentrated facility locations(p.361)
- • Multiple outstanding litigation matters including criminal proceedings(p.357)
- • Outstanding medical negligence claims with significant compensation sought(p.355)
- • Fire safety and building regularisation issues at key facility(p.30)
Opportunities
- • Strong projected growth in Indian healthcare delivery market(p.20)
- • Growing inpatient revenue contribution(p.20)
- • Expansion into southern, central and eastern India markets(p.41)
- • Growth through acquisitions and new hospital development(p.41)
- • Expansion through asset-light models and management arrangements(p.41)
- • Expansion into underserved Tier-II and Tier-III cities(p.138)
- • Rising incidence of non-communicable diseases driving tertiary care demand(p.130)
- • Healthcare delivery market projected to grow at 17-18% CAGR through FY2024(p.142)
- • Significant government healthcare spending increase and PPP support(p.133)
- • Strong government commitment to expand insurance coverage via PMJAY(p.142)
- • Favorable macroeconomic tailwinds in core operating states Telangana and Andhra Pradesh(p.122)
- • Consolidation potential in India's fragmented healthcare market(p.173)
- • Expansion into adjacent markets with high growth potential(p.174)
- • Low insurance penetration in AP at 4% and Telangana at 12% offers growth runway(p.173)
- • Private hospital share expected to increase from 68% to 72% by FY24(p.143)
- • PMJAY scheme will unleash additional demand benefiting private sector(p.143)
- • Growing elderly population increasing healthcare demand with 60+ age group to reach 13% by 2026(p.148)
- • Rising income levels will drive healthcare affordability and demand increase(p.149)
- • Digital healthcare and telemedicine adoption accelerating post-COVID(p.146)
- • Expansion through government healthcare schemes(p.200)
- • Telemedicine expansion enabled by regulatory framework(p.195)
- • Expansion of hospital network through acquisition of subsidiaries with controlling stakes(p.278)
- • Proposed IPO to unlock value and provide exit for investors(p.250)
- • Growing pharmacy and non-hospital revenue streams(p.283)
- • Capital investment in property, plant and equipment and medical equipment(p.285)
- • Strategic expansion in high-growth Tier 2-3 cities with underserved healthcare markets(p.323)
- • Acquisition of standalone hospitals to consolidate fragmented healthcare market(p.323)
- • Recovery and normalization of outpatient volumes post-COVID-19 pandemic(p.327)
- • Government vaccination programs driving incremental patient volumes to hospitals(p.327)
- • Recent acquisitions creating new growth platforms (KHKPL, ICIMSPL, SIMSPL with strong pipeline)(p.301)
- • Mature hospital networks showing strong revenue growth (60.92% CAGR for newer hospitals in 2019-2021)(p.324)
- • Revenue growth through acquisition and operational integration(p.348)
- • Expansion of pharmacy and allied services(p.346)
- • Cost management and operational efficiency improvements(p.347)
Threats
- • COVID-19 pandemic severely reduced patient volumes(p.32)
- • Government price caps on COVID-19 treatment rates(p.33)
- • Regulatory action and potential restrictions on COVID-19 treatment(p.33)
- • Intense competition from large national and regional healthcare providers(p.38)
- • Regulatory compliance requirements in highly regulated healthcare industry(p.37)
- • Geographic concentration risk in AP and Telangana(p.33)
- • Lease expiry risk on key hospital properties(p.34)
- • Interest rate sensitivity on variable rate debt(p.36)
- • Potential trademark/brand infringement from other institutions using KIMS name(p.38)
- • Non-timely payments from payers affecting cash flows(p.40)
- • Risk of regulatory changes and pricing restrictions(p.40)
- • Medical negligence and malpractice litigation exposure(p.41)
- • Dependence on third-party equipment suppliers with limited alternatives(p.42)
- • Inability to expand to new geographic areas and manage new facilities(p.41)
- • Competition in healthcare industry affecting market position(p.44)
- • Pharmaceutical pricing regulation affecting profitability(p.48)
- • Government regulation of healthcare pricing and margins(p.56)
- • Shortage of qualified healthcare professionals(p.56)
- • Health pandemics and temporary requisitioning of facilities(p.56)
- • Indian tax law changes affecting profitability and operations(p.57)
- • Low health insurance penetration limiting patient payment capacity(p.50)
- • Economic slowdown affecting disposable income for healthcare services(p.56)
- • Civil disturbances and regional conflicts affecting business(p.59)
- • India's healthcare expenditure significantly lags global and emerging market peers(p.124)
- • Critical shortage of healthcare infrastructure and medical personnel(p.125)
- • High out-of-pocket healthcare spending limiting demand and creating affordability risk(p.125)
- • Intense competitive consolidation among hospital chains(p.141)
- • Regulatory risk from healthcare regulations and compliance requirements(p.141)
- • COVID-19 pandemic creating near-term operational challenges for private hospitals(p.142)
- • India's healthcare infrastructure lags global benchmarks creating regulatory pressure(p.147)
- • Government price capping on medical devices and services eroding margins(p.152)
- • Outstanding receivables from government schemes weakening hospital finances(p.152)
- • Severe shortage of qualified medical professionals in India(p.152)
- • COVID-19 pandemic causing 10-15% decline in private hospital revenues(p.143)
- • Hospital margins eroding by 400-500 basis points due to fixed cost structure(p.145)
- • Rising out-of-pocket expenditure driving 60-80 million people into poverty annually(p.151)
- • Competition from established pan-India hospital chains and regional players(p.190)
- • Strict regulatory compliance requirements for medical operations(p.194)
- • Mandatory biomedical waste management compliance(p.197)
- • Environmental and pollution control compliance obligations(p.197)
- • Complex licensing requirements for narcotic drugs(p.195)
- • Regulatory risk from draft digital health legislation(p.197)
- • Litigation and regulatory disputes including consumer claims and tax matters(p.285)
- • Property acquisition threat for road widening in Nellore despite court stay(p.285)
- • Rising employee benefit costs and compensation obligations(p.284)
- • Significant operating lease obligations with long-term commitments(p.286)
- • Uncertainty regarding Supreme Court guidance on Provident Fund withholding obligations(p.285)
- • Regulatory uncertainty and price controls on healthcare services impacting margins(p.326)
- • GST implementation removing input credit for healthcare services reducing operating margins(p.326)
- • Government pharmaceutical pricing policies affecting pharmacy profit margins(p.326)
- • COVID-19 pandemic causing continued inpatient and outpatient volume volatility(p.327)
- • Interest rate risk from variable rate borrowings of ₹2,201.64 million creating earnings volatility(p.300)
- • Upward trend in healthcare industry wages and operating costs reducing profitability(p.325)
- • Liquidity risk with material near-term maturities of ₹2,411.52 million due within one year(p.300)
- • Regulatory risks related to healthcare licensing and compliance(p.361)
- • Environmental and pollution control compliance requirements(p.362)
- • Interest rate volatility affecting borrowing costs(p.352)
- • Intellectual property infringement and trademark opposition proceedings(p.356)
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Dr. Bhaskara Rao Bollineni | Promoter | 27.59% | — |
| Rajyasri Bollineni | Promoter | 2.77% | — |
| Dr. Abhinay Bollineni | Promoter | 0.06% | — |
| Adwik Bollineni | Promoter | 0.01% | — |
| Bollineni Ramanaiah Memorial Hospitals Private Limited | Promoter/Corporate Promoter | 6.74% | — |
| General Atlantic Singapore KH Pte. Ltd | Investor Selling Shareholder | 38.41% | — |
| Dr. Bhaskara Rao Bollineni | Promoter | — | approximately 38.84% (as part of Promoter Group) |
| Dr. Abhinay Bollineni | Promoter | — | approximately 38.84% (as part of Promoter Group) |
| Krishnaiah Bollineni | Promoter Group | — | approximately 38.84% (as part of Promoter Group) |
| Seenaiah Bollineni | Promoter Group | — | approximately 38.84% (as part of Promoter Group) |
| Rajyasri Bollineni | Promoter Selling Shareholder | — | — |
| BRMH | Promoter Selling Shareholder | — | — |
| Dr. Bhaskara Rao Bollineni | Promoter | 27.59% | 26.27% |
| BRMH | Corporate Promoter | 6.74% | 6.05% |
| Rajyasri Bollineni | Promoter | 2.77% | 1.72% |
| Dr. Abhinay Bollineni | Promoter | 0.06% | 0.06% |
| Adwik Bollineni | Promoter | 0.01% | 0.01% |
| Dr. Bhaskara Rao Bollineni | Founder/Promoter | — | — |
| Dr. Abhinay Bollineni | Promoter Group/Executive Director | — | — |
| Dr. Bhaskara Rao Bollineni | Promoter | — | — |
| Rajyasri Bollineni | Promoter | — | — |
| Dr. Abhinay Bollineni | Promoter | — | — |
| Adwik Bollineni | Promoter | — | — |
| Bollineni Ramanaiah Memorial Hospitals Private Limited | Corporate Promoter | — | — |
| Dr. B Bhaskar Rao | Promoter | 24.57% | 27.59% |
| General Atlantic Singapore KH Pte Ltd | Promoter Group | 42.61% | 40.91% |
| B. Seenaiah | Promoter | 6.15% | 5.91% |
| Bollineni Ramanaiah Memorial Hospitals Private Limited | Promoter Group | 7.02% | 6.74% |
| Dr. Bhaskara Rao Bollineni | Promoter | — | — |
| Dr. Abhinay Bollineni | Promoter | — | — |
| Dr. Bhaskara Rao Bollineni | Promoter | — | — |
| Bollineni Ramanaiah Memorial Hospitals Private Limited (BRMH) | Promoter Group | — | — |
| Dr. Bhaskara Rao Bollineni | Promoter/Promoter Group | — | — |
| Rajyasri Bollineni | Promoter/Promoter Group | — | — |
| Bollineni Ramanaiah Memorial Hospitals Private Limited (BRMH) | Corporate Promoter Selling Shareholder | — | — |
| General Atlantic Singapore KH Pte. Ltd. | Investor Selling Shareholder | — | — |
Leadership
Dr. Bhaskara Rao Bollineni · Promoter
Rajyasri Bollineni · Promoter
Dr. Abhinay Bollineni · Promoter
Adwik Bollineni · Promoter
Bollineni Ramanaiah Memorial Hospitals Private Limited · Promoter
Vikas Maheshwari · CFO
Umashankar Mantha · Company Secretary and Compliance Officer
Auto-extracted from the company's RHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official RHP before relying on it.
Krishna Institute of Medical Sciences IPO FAQs
What is the lot size of Krishna Institute of Medical Sciences IPO?
The minimum lot size of Krishna Institute of Medical Sciences IPO is 18 shares. One lot costs ₹14,850 at the cut-off price.
When does Krishna Institute of Medical Sciences IPO open and close?
Krishna Institute of Medical Sciences IPO opened for subscription on 16 Jun 2021 and closed on 18 Jun 2021.
What is the listing date of Krishna Institute of Medical Sciences IPO?
Krishna Institute of Medical Sciences IPO listed on 28 Jun 2021.